SAN DIEGO–(BUSINESS WIRE)–Mirador Therapeutics announced it has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
